Janux Therapeutics, Inc. (JANX) Revenue History
Annual and quarterly revenue from 2019 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
JANX Revenue Growth
JANX Revenue Analysis (2019–2025)
As of May 8, 2026, Janux Therapeutics, Inc. (JANX) generated trailing twelve-month (TTM) revenue of $17.9 million. The most recent quarter (Q4 2025) recorded $7.9 million in revenue, down 21.2% sequentially.
Looking at the longer-term picture, JANX's historical revenue data shows a 3-year CAGR of +5.1%. The company achieved its highest annual revenue of $10.6 million in 2024.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), RCUS (+67.4% YoY), and TNGX (+48.3% YoY). Compare JANX vs KYMR →
JANX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| JANXCurrent | $18M | - | - | -1576.7% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 TNGX | $62M | +48.3% | +52.1% | -178.4% |
JANX Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $10.0M | -5.6% | $0 | - | $-157,667,000 | -1576.7% |
| 2024 | $10.6M | +31.0% | $8.5M | 80.5% | $-98,847,000 | -933.6% |
| 2023 | $8.1M | -6.1% | $6.1M | 75.8% | $-72,979,000 | -902.9% |
| 2022 | $8.6M | +136.8% | $7.8M | 90.2% | $-67,091,000 | -779.0% |
| 2021 | $3.6M | - | $3.6M | 100.0% | $-32,929,000 | -905.4% |
| 2020 | $0 | - | $-13,000 | - | $-4,843,000 | - |
| 2019 | $0 | - | $-6,000 | - | $-3,771,000 | - |
See JANX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JANX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare JANX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonJANX — Frequently Asked Questions
Quick answers to the most common questions about buying JANX stock.
Is JANX's revenue growth accelerating or slowing?
JANX TTM revenue: $18M. YoY growth: N/A. 5-year CAGR: N/A.
What is JANX's long-term revenue growth rate?
Janux Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is JANX's revenue distributed by segment?
JANX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2019-2025 are available for download. Segment mix reveals concentration and diversification trends.